VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
NUSNu Skin Enterprises, Inc.
$5.25$255M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksNUSCash Flow

Nu Skin Enterprises, Inc. (NUS) Cash Flow Statement

30Y historyFree accessUpdated daily

Free cash flow has deteriorated significantly, resulting in a negative $17.6 million outflow in 2026Q1 while the company simultaneously returned $7.9 million to shareholders.

NUS Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Cash from Operations75.98M80.29M111.74M118.64M108.06M141.58M379.14M177.93M202.74M302.56M275.26M322.11M-56.46M530.18M310.98M224.31M187.88M133.94M103.31M48.65M75.8M114.1M130.35M109.03M111.12M74.42M43.39M30.3M118.6M92.7M121.2M
Operating CF Margin %-5.41%6.45%6.02%4.86%5.25%14.68%7.35%7.57%13.28%12.47%14.33%-2.2%16.69%14.33%12.86%12.22%10.06%8.28%4.2%6.8%9.66%11.46%11.05%11.53%8.4%4.93%3.39%12.98%10.41%17.86%
Operating CF Growth %-1185.66%-28.15%-5.81%9.79%-23.68%-62.66%113.08%-12.24%-32.99%9.91%-14.54%670.47%-110.65%70.49%38.63%19.39%40.27%29.66%112.33%-35.81%-33.57%-12.47%19.56%-1.88%49.32%71.52%43.19%-74.45%27.94%-23.51%86.46%
Net Income54.52M160.2M-146.59M8.6M104.78M147.27M191.35M173.55M121.89M129.44M143.09M133.05M189.18M364.89M221.65M153.33M136.05M89.84M65.35M43.87M32.82M74.03M77.67M67.88M64.84M50.31M61.7M86.7M103.9M93.6M81.7M
Depreciation & Amortization50.4M52.26M69.81M70.92M72.51M76.32M73.99M76.65M83M71.56M72.4M71.36M54.92M34.92M33.41M32.85M29.62M28.56M30.39M32.97M29.13M31.37M28.66M23.08M21.6M32.43M37.6M33.2M41M24M5.4M
Stock-Based Compensation14.8M24.11M14.82M15.65M12.37M23.19M24.06M9.91M26.61M19.31M8.89M7.4M17.5M32.62M21.36M15.45M10.84M9.99M7.27M9.3M9.3M907K715K715K747K000000
Deferred Taxes-5.7M20K-55.48M-18.09M-51.63M5.82M-11.91M1.97M-14.93M39.21M-17.65M17.36M10.4M-41.75M4.69M108K-13.73M12.35M1.77B1.84M1.84M00-715K-747K000000
Other Non-Cash Items48.2M-86.69M257.51M123.25M62.71M82.6M49.09M48.29M58.05M-4.06M40.22M27.23M53.83M-1.08M-3.87M36.92M3.68M-1.97M-1.75B-3.01M17.15M-907K-715K525K-1.33M-2.33M0100K16.8M100K400K
Working Capital Changes-86.24M-69.62M-28.34M-81.68M-92.67M-193.62M52.56M-132.44M-71.88M47.09M28.32M65.7M-382.3M140.57M33.74M-14.34M21.43M-4.83M-18.11M-36.31M-14.44M8.7M24.02M17.54M26M-5.99M-55.91M-89.7M-43.1M-25M33.7M
Change in Receivables10.2M10.05M-7.76M-22.68M-11.45M20.22M-11.21M2.75M-10.45M-103K3.36M-2.25M30.77M-34.3M-7.88M-5.89M-6.65M-7.04M7.07M-2.79M-2.79M-626K3.86M3.86M-1.13M000000
Change in Inventory6.04M11.89M30.32M-13.22M40.31M-95.32M-31.14M18.45M-33.37M7.54M9.8M59.65M-16.52M-207.44M-22.61M2.42M-4.29M9.74M-14.91M-12.31M163K-11.93M-4.14M4.97M-4.05M-2.24M3.74M-2.1M-3.6M-7.6M-12.2M
Change in Payables-4.92M-9.11M-7.29M-10.08M9.26M-13.28M24.84M-7.18M-9.16M6.83M13.44M-4.3M-45.95M32.64M15.83M6.08M-568K3.6M-6.14M118K118K-4.91M824K824K-1.1M000000
Cash from Investing-25.17M170.66M-37.96M-134.5M-67.08M-88.73M-79.43M-71.41M-108.76M-91.96M-57.86M-60.85M-91.67M-193.7M-104.86M-71.2M-53.78M-20.21M-10.78M-27.96M-37.66M-26.2M-48.18M-23.52M-26.53M-15.13M-22.97M-44M-46.1M-20.7M-11.1M
Capital Expenditures-34.41M-34.28M-41.58M-58.49M-59.06M-68.61M-63.82M-66.07M-70.37M-60.16M-50.22M-56.62M-101.48M-185.1M-96.64M-41.81M-53.78M-20.21M-16.01M-22.74M-37.66M-30.88M-35M-23.52M-19.03M-15.13M-23.03M-43.3M-47.1M-7.4M-5.7M
CapEx % of Revenue2.39%2.31%2.4%2.97%2.65%2.55%2.47%2.73%2.63%2.64%2.27%2.52%3.95%5.83%4.45%2.4%3.5%1.52%1.28%1.96%3.38%2.62%3.08%2.38%1.97%1.71%2.62%4.84%5.16%0.83%0.84%
Acquisitions000-77.28M8.02M-18.96M-14.95M-8.07M-38.51M-31.75M-8.69M0012.56M-12.56M-11.66M0001.98M1.98M0000000000
Investments-------------------------------
Other Investing1M194.72M00-8.02M000116K-63K1.05M-4.22M9.81M-12.56M-8.21M-11.66M0-5.22M0-1.98M-1.98M-5.55M00-7.5M060K-700K1M-13.3M-5.4M
Cash from Financing-56.51M-202.4M-133.18M10.73M-99.5M-104.7M-245.17M-154.79M-116.71M-159.57M-134.71M-235.92M-41.08M-120.72M-163.89M-107.01M-69.02M-73.01M-62.69M-57.63M-74.62M-30.94M-94.55M-87.97M-32.49M-33.77M-65.29M-73.5M-48.7M-91.7M36.7M
Debt Issued (Net)-16.24M-170M-112.89M96.8M25.58M38.13M-28.21M-69.45M29.9M-36.23M177.57M709K82.38M11.1M73.64M-28M-7.4M-30.19M-32.71M33.11M13.39M12.93M-16.24M75M-14.16M0-52.82M-14.5M-40.1M-71.5M-15M
Equity Issued (Net)-21.96M-21.95M-2.06M-8.45M-70.05M-80.42M-144.33M-825K-69.56M-71.73M-247.21M-164.09M-48.14M-140.87M-201.47M-37.44M-37.34M-21.14M-6.09M-71.1M-62.05M-18.46M-55.68M-141.12M1.26M-17.33M-12.47M-24M-8.5M-20.3M98.8M
Dividends Paid-11.71M-11.83M-11.93M-77.62M-77.02M-76.27M-78.39M-82.19M-80.58M-76.06M-78.44M-81.19M-81.37M-70.51M-48.37M-36.64M-31.19M-29.01M-27.94M-27.14M-27.79M-25.41M-22.63M-21.85M-19.59M-16.43M0000-47.1M
Share Repurchases-20.05M-20.04M-2.06M-13.01M-70.05M-80.42M-144.33M-825K-69.56M-71.73M-247.21M-164.09M-45.72M-140.87M-201.47M-67.15M-58.52M-21.14M-6.09M-71.1M-67.45M-24.64M-72.31M-150.01M0-18.14M-12.77M-26.9M-10.5M-20.3M0
Other Financing-6.61M1.38M-6.3M021.98M13.86M5.76M-2.33M3.53M24.44M13.36M8.65M6.06M79.56M12.31M-4.94M6.91M7.33M4.05M7.5M1.84M0000-16.43M0-35M-100K-19.1M32.9M
Net Change in Cash-5.12M51.75M-69.17M-8.67M-74.87M-63.09M67.05M-51.28M-39.49M69.15M67.89M939K-236.74M205.13M47.05M42.64M72.29M43.46M27.26M-34.03M-34.06M45.54M-12.7M2.23M44.42M11.93M-46.17M-78.6M14.5M-40.8M143.9M
Free Cash Flow41.57M46.01M70.16M60.15M49.01M72.97M315.32M111.86M132.37M242.4M225.04M265.49M-157.94M345.07M214.33M182.51M134.1M113.73M87.3M25.92M38.13M83.22M95.35M85.51M92.09M59.29M20.36M-13M71.5M85.3M115.5M
FCF Margin %2.88%3.1%4.05%3.05%2.2%2.71%12.21%4.62%4.94%10.64%10.19%11.81%-6.15%10.86%9.88%10.46%8.72%8.54%7%2.24%3.42%7.05%8.38%8.67%9.55%6.69%2.31%-1.45%7.83%9.58%17.02%
FCF Growth %-36.94%-34.42%16.64%22.74%-32.84%-76.86%181.88%-15.49%-45.39%7.71%-15.23%268.09%-145.77%61%17.44%36.1%17.91%30.27%236.84%-32.04%-54.17%-12.73%11.51%-7.15%55.32%191.24%256.6%-118.18%-16.18%-26.15%93.79%
FCF per Share0.840.911.411.210.971.425.982.002.344.424.014.50-2.595.623.402.832.081.771.360.400.541.171.311.081.110.710.24-0.150.820.981.39
FCF Conversion (FCF/Net Income)0.76x0.50x-0.76x13.80x1.03x0.96x1.98x1.03x1.66x2.34x1.92x2.42x-0.30x1.45x1.40x1.46x1.38x1.49x1.58x1.11x2.31x1.54x1.68x1.61x1.71x1.48x0.70x0.35x1.14x0.99x1.48x
Interest Paid16.7M000000000000000000000000000000
Taxes Paid0000000000000000000000000000000

Key Metrics

Growth RegimeContracting
ProfitabilityStrained
Balance SheetHealthy
Cash FlowDeteriorating
Top Statement Risk

Operational cash flow volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality and Cash Divergence

As reported in recent financial filings, Nu Skin's operating cash flow to net income ratio has exhibited extreme volatility, including a negative 2.13x reading in 2026Q1, which suggests that reported accounting profits are frequently decoupled from the actual cash generated by the underlying business operations.

The persistent gap between net income and operating cash flow indicates that earnings are heavily influenced by non-cash adjustments or timing differences in working capital. Investors should monitor whether this divergence reflects structural difficulties in converting sales into realized cash or merely temporary accounting fluctuations.

Free Cash Flow Margin Erosion

Based on the provided quarterly data, Nu Skin's free cash flow trajectory has turned increasingly negative, with FCF margins dropping to -5.5% in 2026Q1, signaling a significant deterioration in the company's ability to fund operations and shareholder returns through internal cash generation alone.

The shift from positive FCF in previous periods to recent outflows suggests that the company's cost structure is not scaling down in proportion to its revenue contraction. This trend warrants further investigation into whether the current capital allocation strategy remains sustainable without further balance sheet depletion.

Working Capital Volatility and Drag

According to historical cash flow statements, Nu Skin has faced significant working capital headwinds, highlighted by a $35.5 million outflow in 2026Q1, which suggests that inventory management and collection cycles are becoming increasingly inefficient as the company navigates a period of sustained top-line contraction.

The erratic nature of working capital changes implies that the company may be struggling to balance inventory levels with fluctuating distributor demand. Such volatility often precedes further margin pressure if the company is forced to liquidate excess inventory or extend credit terms to maintain sales leader engagement.

Capital Allocation Amidst Declining Cash

As indicated by recent financial statements, Nu Skin continues to prioritize dividends and share repurchases despite a deteriorating cash flow profile, with $7.9 million returned to shareholders in 2026Q1 even as the company reported a negative free cash flow of $17.6 million during the same period.

This deployment strategy appears aggressive given the current revenue headwinds and suggests that management may be relying on existing cash reserves rather than operational cash flow to fund shareholder returns. Investors should monitor the sustainability of this payout policy if the current cash burn persists.

NUS — Frequently Asked Questions

Quick answers to the most common questions about buying NUS stock.

How much cash does Nu Skin Enterprises, Inc. (NUS) generate from operations?

Nu Skin Enterprises, Inc. (NUS) generated $80.3M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Nu Skin Enterprises, Inc.'s free cash flow?

Nu Skin Enterprises, Inc. (NUS) generated $46.0M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Nu Skin Enterprises, Inc.'s capital expenditure (CapEx)?

Nu Skin Enterprises, Inc. (NUS) spent $34.3M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Nu Skin Enterprises, Inc. distribute cash to shareholders?

In 2025, Nu Skin Enterprises, Inc. (NUS) returned $11.8M to shareholders via cash dividends and spent $20.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.